115 related articles for article (PubMed ID: 15174030)
1. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.
Deng Y; Newman B; Dunne MP; Silburn PA; Mellick GD
Ann Neurol; 2004 Jun; 55(6):897. PubMed ID: 15174030
[No Abstract] [Full Text] [Related]
2. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.
Elbaz A; Levecque C; Clavel J; Vidal JS; Richard F; Amouyel P; Alpérovitch A; Chartier-Harlin MC; Tzourio C
Ann Neurol; 2004 Mar; 55(3):430-4. PubMed ID: 14991823
[TBL] [Abstract][Full Text] [Related]
3. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
4. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
6. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
7. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
Tao E; Liu Z; Chen B; Pan X; Shao M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
[TBL] [Abstract][Full Text] [Related]
8. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
Santt O; Baranova H; Albuisson E; Bignon YJ; Lucotte G
Eur J Neurol; 2004 Apr; 11(4):247-51. PubMed ID: 15061826
[TBL] [Abstract][Full Text] [Related]
9. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease.
Taanman JW; Schapira AH
Neurosci Lett; 2005 Mar; 376(1):56-9. PubMed ID: 15694274
[TBL] [Abstract][Full Text] [Related]
11. Glutathione-S-transferase-1 and interleukin-1beta gene polymorphisms in Japanese patients with Parkinson's disease.
Nishimura M; Kuno S; Kaji R; Yasuno K; Kawakami H
Mov Disord; 2005 Jul; 20(7):901-2. PubMed ID: 15834859
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
15. [Genetic polymorphism of CYP-1A1, CYP2D6 and risks of chronic benzene poisoning].
Gu SY; Zhang ZB; Cao DZ; Wan JX; Gao XL; Jin XP; Xia ZL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 May; 24(5):266-9. PubMed ID: 16737584
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population.
Huerta C; Castro MG; Coto E; Blázquez M; Ribacoba R; Guisasola LM; Salvador C; Martínez C; Lahoz CH; Alvarez V
J Neurol Sci; 2005 Sep; 236(1-2):49-54. PubMed ID: 15975594
[TBL] [Abstract][Full Text] [Related]
17. 5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study.
Kelada SN; Checkoway H; Kardia SL; Carlson CS; Costa-Mallen P; Eaton DL; Firestone J; Powers KM; Swanson PD; Franklin GM; Longstreth WT; Weller TS; Afsharinejad Z; Costa LG
Hum Mol Genet; 2006 Oct; 15(20):3055-62. PubMed ID: 16963468
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
19. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease.
Deng H; Xie W; Guo Y; Le W; Jankovic J
Mov Disord; 2006 May; 21(5):728-9. PubMed ID: 16552756
[No Abstract] [Full Text] [Related]
20. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure.
Galanaud JP; Elbaz A; Clavel J; Vidal JS; Corrèze JR; Alpérovitch A; Tzourio C
Mov Disord; 2005 Feb; 20(2):181-9. PubMed ID: 15468111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
